IQVIA, a global leader in healthcare and clinical research services, has unveiled a suite of custom-built AI agents at GTC Paris, developed in collaboration with NVIDIA. These agents are designed to optimise workflows and accelerate insight generation across the life sciences industry, leveraging NVIDIA’s technology and IQVIA’s extensive healthcare data and domain expertise. The collaboration focuses on applying agentic AI – a system where AI autonomously performs tasks – to critical areas such as target identification, clinical data review, and market assessment, with the aim of streamlining processes from initial research through to commercial deployment. This initiative builds upon a strategic partnership announced in January, signalling a significant advancement in the application of artificial intelligence to enhance the efficiency and precision of pharmaceutical research and healthcare delivery.
IQVIA and NVIDIA are collaborating to develop custom-built artificial intelligence (AI) agents designed to optimise workflows and accelerate insight generation within the life sciences industry. This partnership leverages NVIDIA’s technology, including NIM Agent Blueprints, NeMo Customizer, and NeMo Guardrails, to address challenges across the entire life sciences continuum. By integrating these tools with IQVIA’s extensive healthcare data and domain expertise, the collaboration aims to deliver enhanced precision, efficiency, and focus to clinical trials and commercial launches.
IQVIA delivers a comprehensive suite of capabilities centred around clinical research, commercial insights, and healthcare intelligence for the life sciences and healthcare sectors. These services are underpinned by IQVIA Connected Intelligence, a system integrating high-quality health data, Healthcare-grade Artificial Intelligence (AI), advanced analytics, and extensive domain expertise to generate actionable insights. IQVIA is actively developing and deploying these custom AI agents, applying them to use cases including target identification, clinical data review, literature synthesis, market assessment, and healthcare professional (HCP) engagement.
A key component of IQVIA’s approach is the application of AI trained on its vast, healthcare-specific information resources. This allows the company to streamline and focus clinical trials and commercial launches, providing powerful workflow coordination and insights to its customer base. IQVIA prioritises responsible AI implementation, adhering to best-in-class practices regarding privacy, regulatory compliance, and patient safety, and delivering AI solutions that meet the industry’s demands for trust, scalability, and precision.
These AI agents are designed to optimise workflows and accelerate insight generation throughout the life sciences pipeline. Specific applications include streamlining literature reviews, facilitating clinical data analysis, and enhancing engagement with healthcare professionals. By employing AI to sift through vast quantities of scientific publications and clinical data, IQVIA aims to provide its customers with rapid access to relevant information, facilitating quicker decision-making and accelerating the pace of discovery. Market assessment also benefits from this technology, allowing for more nuanced and timely evaluations of potential opportunities.
IQVIA will showcase its newly developed AI agents at NVIDIA’s GTC Paris conference, demonstrating applications designed to optimise workflows and accelerate insight generation within the life sciences sector. Following the GTC Paris event, IQVIA will host TechIQ 2025 in London in September. This two-day conference will provide a platform for industry leaders, including representatives from NVIDIA, to discuss strategic approaches to integrating AI into life sciences, and will explore the evolving landscape of AI-driven innovation in healthcare. The event is designed to facilitate knowledge sharing and collaboration on navigating the future of AI within the sector.
With a workforce of approximately 88,000 employees operating in over 100 countries, IQVIA possesses a diverse range of expertise encompassing healthcare, life sciences, data science, technology, and operational excellence. This broad skillset enables the company to deliver comprehensive solutions and support its clients throughout the entire asset lifecycle, from initial research and development to commercialisation and post-market surveillance.
More information
External Link: Click Here For More
